RxConsultant.com

Save time, stay current, and earn CE. You can rely on The Rx Consultant to deliver practical easy-reading updates on drugs & therapy for front-line pharmacists and nurses.

CE for this article is no longer valid.
Non Subscriber: Buy This Issue

Osteoporosis Management

Clicking the "View this Article" button will open the issue as a resizable PDF. To take the test for the issue, return to this Introduction page and click the "Take the Test" button. The Introduction page will remain open after you open this issue. You may need to re-size or close the issue in order to see the Introduction page.

Overview

   Osteoporosis is the most common bone disease and threatens an estimated 44 million Americans. Of these, 10 million suffer from osteoporosis and 34 million are at risk for fracture due to low bone mass (osteopenia). Half of all postmenopausal women and 1 in 5 men over the age of 50 will have an osteoporosis-related fracture in their lifetimes. The most common sites for these fractures are the spine, hip, and wrist. Hip fractures are particularly devastating, with a 10-20% risk of death in the year following the fracture.

Osteoporosis is more prevalent in women than men; however, the impact of osteoporosis among older men is commonly underestimated. Osteoporosis affects more men than prostate cancer (the most common cancer in men) and is more likely to result in disability or death.

   This issue focuses on the drug and nondrug therapies recommended for osteoporosis prevention and treatment. The management of osteoporosis resulting from long-term glucocorticoid therapy is included. The potential benefits, side effects, drug interactions, and optimal use of bisphosphonates, raloxifene, calcitonin, teriparatide, and estrogen replacement therapy are reviewed with key information presented in easy-to-read tables. Risk factors for osteoporosis and the criteria that are used to select candidates for bone mineral density (BMD) testing and drug therapy are also discussed.

Details

Publication Date: 03/01/2009
Expiration Date: 03/01/2012
CE Credit: 1.5 (0.15 CEU)
Type of Activity: Knowledge-based

This program was developed by The Rx Consultant and published by Continuing Education Network, Inc. The Rx Consultant accepts no advertising or financial support from the pharmaceutical industry and is funded solely by the purchase of programs. The Rx Consultant is dedicated to providing unbiased, balanced information to health care practitioners.

Programs developed by The Rx Consultant are written by health care providers with expertise in the topic area, peer-reviewed, extensively edited, and fact-checked. This development process was created to insure that every program presents information that is current, accurate, relevant to "real world" health care providers, and written in an easy reading, "plain English" style.

Authors

Kimberly M. Crosby, PharmD, BCPS, CGP, Clinical Assistant Professor, The University of Oklahoma College of Pharmacy and Clinical Coordinator, USA Drug/May's Drugstrores; Michelle Lamb, PharmD, Community Pharmacy Practice Resident, USA Drug/University of Oklahoma College of Pharmacy, and Katherine O'Neal, PharmD, MBA, Community Pharmacy Practice Resident, USA Drug/University of Oklahoma College of Pharmacy, Tulsa, OK. Guest Editor: Leslie A. Shimp, PharmD, MS

Disclosure Statement

Dr. Crosby, Dr. Lamb and Dr. O'Neal report no financial or personal relationship with any commercial interest producing, marketing, reselling, or distributing a product or service that appears in this issue.

Guest Editorial Advisor

Leslie A. Shimp, PharmD, MS

Target Audience

This accredited program is targeted to pharmacists and nurses.

Goals & Objectives

At the conclusion of this program, participants will be able to:

    1. Assess a patient’s risk for osteoporosis by identifying modifiable and nonmodifiable risk factors. List criteria that are used to select candidates for BMD testing.
    2. Describe the role of non-drug therapy and FDA-approved medications in the prevention and treatment of osteoporosis.
    3. Educate patients about the use of bisphosphonates, raloxifene, calcitonin, teriparatide, and estrogen replacement therapy including potential benefits, side effects, drug interactions, and appropriate administration.

Accreditation Statements

The Rx Consultant is a publication of Continuing Education Network, Inc. Continuing Education Network, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education as a provider of continuing pharmacy education.

Continuing Education Network is approved by the California Board of Registered Nursing, Provider Number CEP 13118. Programs approved by CA BRN are accepted by most State Boards of Nursing.

Exam & Credit Statement Procedures

Upon successful completion of this program and the post test (70%), 1.5 hours of continuing education credit will be awarded. To receive credit and your exam score, please complete the exam questions and program evaluation.

Editorial and Review Board

Editor and CE Administrator

Terry M. Baker, PharmD

Associate Editor and CE Coordinator

Tracy Farnen, PharmD

Associate Editors

James Chan, PharmD, PhD
Pharmacy Quality and Outcomes Coordinator
Kaiser Permanente
Oakland, CA

Associate Clinical Professor
School of Pharmacy
University of California San Francisco
San Francisco, CA

Ron Finley, RPh
Lecturer
Department of Clinical Pharmacy
University of California San Francisco
San Francisco, CA

Associate Member of the UCSF Memory and Aging Center
Alzheimer's Research Center

Consultant Pharmacist to the Institute on Aging-On Lok Senior Health
Institute on Aging Alzheimer's Day Care Center

Angie S. Graham, PharmD
Drug Information Coordinator
Stanford Hospital and Clinics
Stanford University Medical Center
Stanford, CA

Julio R. Lopez, PharmD, FCSHP
Chief of Pharmacy Service
VA Northern California Health Care System

Adjunct Clinical Professor
College of Pharmacy
Touro University
Vallejo, CA

Assistant Clinical Professor
School of Pharmacy
University of California, San Francisco
San Francisco, CA

Adjunct Professor
Thomas J. Long School of Pharmacy
University of the Pacific
Stockton, CA

Visiting Associate Professor and Lecturer
Nursing School
Samuel Merritt University
Oakland, CA

Pamela Mausner, MD

Joshua J. Neumiller, PharmD, CDE, CGP, FASCP
Assistant Professor
Department of Pharmacotherapy
College of Pharmacy
Washington State University
And
Elder Services of Spokane
Spokane, WA

Candy Tsourounis, PharmD
Professor of Clinical Pharmacy
Medication Outcomes Center
Department of Clinical Pharmacy
School of Pharmacy
University of California, San Francisco
San Francisco, CA

Senior Editorial Advisor

Gerard Hatheway, PharmD, PhD

Editorial Advisors

Jocelyn Chan, PharmD
Belinda M. Danielson, RPh
Christopher M. DeSoto, PharmD
Cynthia Chan Huang, PharmD, MBA
Fred Plageman, PharmD


Editorial Advisor and Clinical Practice Consultant for Nurse Practitioners

Emily K. Meuleman, RN, C, MS

About the Rx Consultant

The Rx Consultant is a monthly publication dedicated to providing health care professionals with the information they need to educate patients about drugs and manage drug therapy. The reader is responsible for confirming the information presented here and interpreting it in relation to each patient's specific situation before utilizing the information.

Contact Us

Exam Processing Inquiries

The Rx Consultant
mail@rxconsultant.com
1-800-798-3353

Educational Content Inquiries

The Rx Consultant
editor@rxconsultant.com
1-800-798-3353

CE for this article is no longer valid.
Non Subscriber: Buy This Issue